JD Health bolsters omnichannel, AI, and healthcare innovation in 2024

JD Health International Inc. (HKEX: 6618) today released its 2024 annual report, showcasing significant strides in strengthening its healthcare ecosystem. The company reported a revenue increase of 8.6% to RMB58.2 billion, driven by growth in pharmaceutical and healthcare product sales. JD Health has focused on its omnichannel strategy, enhancing direct sales and integrating online marketplaces with on-demand retail, bringing delivery times to as fast as 9 minutes in some areas. Further, it is rapidly expanding real-time insurance reimbursement for online medical purchases to 18 cities across China.